Replies to post #8491 on Theralink Technologies Inc (THER)

[learningcurve2020]

Why do you say that when clearly there are differences?

Feb

>>We are thrilled to be able to partner with a high-quality provider such as CATO Research as we work together toward the goal of getting PGT accessible to patients with refractory cancers,” commented Dr. Brian Barnett, Chief Executive Officer at OncBioMune.  “We believe, given their experience in drug development, that CATO Research will be instrumental in helping us accomplish the goal of providing new safe and effective alternatives to this patient population with a high unmet medical need.”

May

“We are excited that CATO BioVentures has a belief in our science that would motivate them to become a strategic investor in OncBiomune. We are hopeful that this show of support from such a high quality provider will act as a catalyst to assist us in additional favorable fundraising activities,” commented Dr. Brian Barnett, Chief Executive Officer at OncBioMune.  “It has already been a pleasure working with the team of the CATO Research CRO arm as we start the process of putting together a clinical development plan for our proprietary therapy, PGT, and strive toward the goal of getting PGT accessible to patients with refractory cancers that represents a large area of unmet medical need.”